Cingulate Inc. Stock-Based Compensation
Cingulate Inc. (CING) reported Stock-Based Compensation of $955.33 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Cingulate Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $362.23K, a 93.30% increase year-over-year.
- Cingulate Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $593.10K, a 65.83% increase year-over-year.
- Cingulate Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $385.96K, a 539.55% increase year-over-year.
- Cingulate Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $592.82K, a 50.54% increase year-over-year.
- Cingulate Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $1.52M, a 53.07% increase from fiscal 2024.
- Cingulate Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $995.48K, a 22.50% increase from fiscal 2023.
- Cingulate Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $812.67K, a 1.48% increase from fiscal 2022.
- Cingulate Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $800.80K, a 1726.84% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $362.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $955.33K 10-Q · filed 2026-08-13 | $1.34M derived: sum of 3 quarters · filed 2026-08-13 | $1.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $593.10K 10-Q · filed 2026-05-14 | $979.07K derived: sum of 2 quarters · filed 2026-05-14 | $1.57M derived: sum of 3 quarters · filed 2026-05-14 | $1.76M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $385.96K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $978.79K derived: sum of 2 quarters · filed 2026-03-18 | $1.17M derived: sum of 3 quarters · filed 2026-08-13 | $1.52M 10-K · filed 2026-03-18 |
| 2025-09-30 | $592.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $780.21K derived: sum of 2 quarters · filed 2026-08-13 | $1.14M 10-Q · filed 2025-11-13 | $1.20M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $187.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $545.04K 10-Q · filed 2026-08-13 | $605.39K derived: sum of 3 quarters · filed 2026-08-13 | $999.17K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $357.65K 10-Q · filed 2026-05-14 | $418.00K derived: sum of 2 quarters · filed 2026-05-14 | $811.78K derived: sum of 3 quarters · filed 2026-05-14 | $1.19M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $60.35K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $454.13K derived: sum of 2 quarters · filed 2026-03-18 | $830.91K derived: sum of 3 quarters · filed 2026-03-18 | $995.48K 10-K · filed 2026-03-18 |
| 2024-09-30 | $393.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $770.56K derived: sum of 2 quarters · filed 2025-11-13 | $935.13K 10-Q · filed 2025-11-13 | $1.09M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $376.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $541.35K 10-Q · filed 2025-08-19 | $695.91K derived: sum of 3 quarters · filed 2025-08-19 | $932.16K derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | $164.57K 10-Q · filed 2025-05-08 | $319.14K derived: sum of 2 quarters · filed 2025-05-08 | $555.39K derived: sum of 3 quarters · filed 2025-05-08 | $772.77K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $154.56K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $390.81K derived: sum of 2 quarters · filed 2025-03-27 | $608.19K derived: sum of 3 quarters · filed 2025-03-27 | $812.67K 10-K · filed 2025-03-27 |
| 2023-09-30 | $236.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $453.63K derived: sum of 2 quarters · filed 2024-11-07 | $658.11K 10-Q · filed 2024-11-07 | $864.54K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $217.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $421.86K 10-Q · filed 2024-08-13 | $628.29K derived: sum of 3 quarters · filed 2024-08-13 | $833.95K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $204.48K 10-Q · filed 2024-05-08 | $410.92K derived: sum of 2 quarters · filed 2024-05-08 | $616.57K derived: sum of 3 quarters · filed 2024-05-08 | $823.76K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $206.44K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $412.09K derived: sum of 2 quarters · filed 2024-04-01 | $619.28K derived: sum of 3 quarters · filed 2024-04-01 | $800.80K 10-K · filed 2024-04-01 |
| 2022-09-30 | $205.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $412.84K derived: sum of 2 quarters · filed 2023-11-13 | $594.36K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $207.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $388.70K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $181.52K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $43.84K 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |